

# Andrea Cara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9559196/publications.pdf>

Version: 2024-02-01

92  
papers

4,628  
citations

182225

30  
h-index

120465

65  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4979  
citing authors

#	ARTICLE	IF	CITATIONS
1	Seasonal Betacoronavirus Antibodies™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. <i>Journal of Clinical Immunology</i> , 2022, 42, 448-458.	2.0	7
2	Strong SARS-CoV-2 N-Specific CD8+ T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice. <i>Viruses</i> , 2022, 14, 329.	1.5	11
3	UltraViolet SANitizing System for Sterilization of Ambulances Fleets and for Real-Time Monitoring of Their Sterilization Level. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 331.	1.2	8
4	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. <i>Npj Vaccines</i> , 2022, 7, 44.	2.9	2
5	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1472-1481.	1.8	36
6	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. <i>Viruses</i> , 2021, 13, 355.	1.5	17
7	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. <i>Nature Communications</i> , 2021, 12, 2670.	5.8	297
8	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 23, 263-275.	1.8	4
9	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. <i>Frontiers in Immunology</i> , 2021, 12, 750386.	2.2	6
10	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. <i>Nature Communications</i> , 2021, 12, 6871.	5.8	147
11	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. <i>Frontiers in Immunology</i> , 2020, 11, 603428.	2.2	8
12	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	2.9	11
13	Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. <i>Viruses</i> , 2020, 12, 1460.	1.5	4
14	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020, 5, 36.	2.9	12
15	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 418-428.	1.8	10
16	Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 532-544.	1.8	18
17	Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses. <i>Cell Reports</i> , 2019, 26, 1242-1257.e7.	2.9	23
18	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	2.0	26

#	ARTICLE	IF	CITATIONS
19	Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. <i>Frontiers in Immunology</i> , 2018, 9, 171.	2.2	31
20	A high susceptibility to redox imbalance of the transmissible stages of <i>Plasmodium falciparum</i> revealed with a luciferase-based mature gametocyte assay. <i>Molecular Microbiology</i> , 2017, 104, 306-318.	1.2	28
21	Intranasal Administration of Integrase Defective Lentiviral Vectors Expressing mAbs Protects from H5 Influenza Virus Challenge In Vivo. <i>Open Forum Infectious Diseases</i> , 2017, 4, S520-S521.	0.4	1
22	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	3.7	41
23	HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy. <i>Journal of Medical Virology</i> , 2016, 88, 2115-2124.	2.5	7
24	Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. <i>Aids</i> , 2015, 29, 1651-1657.	1.0	20
25	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. <i>Oncogene</i> , 2015, 34, 5163-5174.	2.6	69
26	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. <i>Retrovirology</i> , 2015, 12, 4.	0.9	35
27	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. <i>PLoS ONE</i> , 2014, 9, e107377.	1.1	12
28	Murine Granulocyte-Macrophage Colony-Stimulating Factor Expressed from a Bicistronic Simian Immunodeficiency Virus-Based Integrase-Defective Lentiviral Vector Does Not Enhance T-Cell Responses in Mice. <i>Viral Immunology</i> , 2014, 27, 512-520.	0.6	1
29	Renal epithelial cells produce and spread HIV-1 via T-cell contact. <i>Aids</i> , 2014, 28, 2345-2353.	1.0	32
30	Multicolor Bioluminescence Boosts Malaria Research: Quantitative Dual-Color Assay and Single-Cell Imaging in <i>Plasmodium falciparum</i> Parasites. <i>Analytical Chemistry</i> , 2014, 86, 8814-8821.	3.2	54
31	Mucosal Immunization with Integrase-Defective Lentiviral Vectors Protects against Influenza Virus Challenge in Mice. <i>PLoS ONE</i> , 2014, 9, e97270.	1.1	17
32	No Evidence of Autoimmune Disorders in Antiretroviral-Experienced HIV-1-Infected Individuals after Long-Term Treatment with Raltegravir. <i>Antiviral Therapy</i> , 2013, 18, 321-327.	0.6	4
33	Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. <i>International Journal of Cancer</i> , 2013, 132, 335-344.	2.3	38
34	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 193-199.	1.3	10
35	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1365-1369.	0.5	2
36	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. <i>International Journal of STD and AIDS</i> , 2012, 23, 459-463.	0.5	10

#	ARTICLE	IF	CITATIONS
37	Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. <i>Retrovirology</i> , 2012, 9, 69.	0.9	21
38	Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines. <i>Retrovirology</i> , 2012, 9, .	0.9	1
39	Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 739-750.	1.4	29
40	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. <i>Vaccine</i> , 2011, 29, 3465-3475.	1.7	17
41	157 Fusion Complexes and CD4-Independent Env for the Induction of Broad Spectrum Neutralizing Antibodies Against HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 65.	0.9	0
42	Toward Integrase Defective Lentiviral Vectors for Genetic Immunization. <i>Current HIV Research</i> , 2010, 8, 274-281.	0.2	18
43	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. <i>Journal of Virological Methods</i> , 2010, 168, 272-276.	1.0	15
44	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8 <sup>+</sup> T Cells. <i>Human Gene Therapy</i> , 2010, 21, 1029-1035.	1.4	32
45	Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7.	3.0	20
46	Integrase Defective, Nonintegrating Lentiviral Vectors. <i>Methods in Molecular Biology</i> , 2010, 614, 101-110.	0.4	12
47	Development and use of SIV-based Integrase defective lentiviral vector for immunization. <i>Vaccine</i> , 2009, 27, 4622-4629.	1.7	41
48	Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. <i>Antiviral Research</i> , 2008, 80, 288-294.	1.9	17
49	Kunjin replicon-based simian immunodeficiency virus gag vaccines. <i>Vaccine</i> , 2008, 26, 3268-3276.	1.7	17
50	<i>Macaca mulatta</i> , <i>Macaca fascicularis</i> and <i>Macaca nemestrina</i> in AIDS vaccine development. <i>Expert Review of Vaccines</i> , 2008, 7, 1419-1434.	2.0	45
51	Human Immunodeficiency Virus Type 1 (HIV-1) Integration: a Potential Target for Microbicides To Prevent Cell-Free or Cell-Associated HIV-1 Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2544-2554.	1.4	22
52	Characterization of $\alpha$ -Defensins Plasma Levels in <i>Macaca Fascicularis</i> and Correlations with Virological Parameters during SHIV89.6Pcy11 Experimental Infection. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 287-296.	0.5	6
53	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. <i>Virus Research</i> , 2007, 126, 86-95.	1.1	3
54	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. <i>Molecular Therapy</i> , 2007, 15, 1716-1723.	3.7	79

#	ARTICLE	IF	CITATIONS
55	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. <i>Retrovirology</i> , 2007, 4, 17.	0.9	20
56	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responses in Vitro and in Vivo. <i>Viral Immunology</i> , 2006, 19, 690-701.	0.6	35
57	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3407-3417.	1.4	18
58	Retroviral E-DNA: persistence and gene expression in nondividing immune cells. <i>Journal of Leukocyte Biology</i> , 2006, 80, 1013-1017.	1.5	31
59	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. <i>Journal of General Virology</i> , 2006, 87, 3385-3392.	1.3	11
60	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1 JR-FL gp120 generates durable immune responses in mice. <i>Journal of General Virology</i> , 2006, 87, 1625-1634.	1.3	26
61	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant 1 <sup>9</sup> V2 Env. <i>Microbes and Infection</i> , 2005, 7, 1392-1399.	1.0	17
62	The impact of telomere erosion on memory CD8 <sup>+</sup> T cells in patients with X-linked lymphoproliferative syndrome. <i>Mechanisms of Ageing and Development</i> , 2005, 126, 855-865.	2.2	72
63	Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4 <sup>+</sup> T lymphocytes: implications for integrase inhibitors. <i>Journal of General Virology</i> , 2005, 86, 765-771.	1.3	29
64	HIV-1 Extrachromosomal 2-LTR Circular DNA Is Long-Lived in Human Macrophages. <i>Viral Immunology</i> , 2005, 18, 190-196.	0.6	65
65	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. <i>Journal of Immunological Methods</i> , 2004, 291, 153-163.	0.6	6
66	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. <i>Virology</i> , 2004, 324, 531-539.	1.1	12
67	Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer. <i>Human Gene Therapy</i> , 2004, 15, 361-372.	1.4	132
68	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. <i>Vaccine</i> , 2004, 22, 3258-3269.	1.7	70
69	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. <i>DNA and Cell Biology</i> , 2002, 21, 599-610.	0.9	35
70	HIV-1 Nef Induces Proliferation and Anchorage-Independent Growth in Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1806-1815.	3.0	137
71	Circular Viral DNA and Anomalous Junction Sequence in PBMC of HIV-Infected Individuals with No Detectable Plasma HIV RNA. <i>Virology</i> , 2002, 292, 1-5.	1.1	31
72	Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. <i>Nature Medicine</i> , 2002, 8, 522-526.	15.2	286

#	ARTICLE	IF	CITATIONS
73	Effect of Tissue Processing on the Ability to Recover Nucleic Acid from Specific Renal Tissue Compartments by Laser Capture Microdissection. <i>Nephron Experimental Nephrology</i> , 2001, 9, 229-234.	2.4	30
74	Development of a Novel Screen for Protease Inhibitors. <i>Vaccine Journal</i> , 2001, 8, 437-440.	2.6	3
75	Human Immunodeficiency Virus-1 Induces Loss of Contact Inhibition in Podocytes. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1677-1684.	3.0	78
76	Engineering viral promoters for gene transfer to human neuroblasts. <i>Cellular and Molecular Neurobiology</i> , 2000, 20, 409-415.	1.7	3
77	Superfibronectin, a Multimeric Form of Fibronectin, Increases HIV Infection of Primary CD4+T Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 3236-3245.	0.4	29
78	Renal Epithelium Is a Previously Unrecognized Site of HIV-1 Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 2079-2087.	3.0	287
79	Level of Human Immunodeficiency Virus DNA in Peripheral Blood Mononuclear Cells Correlates with Efficacy of Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2361-2365.	1.8	31
80	Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector. <i>Gene Therapy</i> , 1998, 5, 65-75.	2.3	21
81	Human T-Cell Lymphotropic/Leukemia Virus Type 1 Tax Abrogates p53-Induced Cell Cycle Arrest and Apoptosis through Its CREB/ATF Functional Domain. <i>Journal of Virology</i> , 1998, 72, 8852-8860.	1.5	168
82	New insight on the role of extrachromosomal retroviral DNA. <i>Leukemia</i> , 1997, 11, 1395-1399.	3.3	40
83	The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. <i>Nature Medicine</i> , 1996, 2, 1244-1247.	15.2	524
84	HIV-1 Protein Expression from Synthetic Circles of DNA Mimicking the Extrachromosomal Forms of Viral DNA. <i>Journal of Biological Chemistry</i> , 1996, 271, 5393-5397.	1.6	57
85	p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. <i>Blood</i> , 1996, 88, 1551-1560.	0.6	16
86	Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. <i>Nature Medicine</i> , 1995, 1, 667-673.	15.2	99
87	Self-Limiting, Cell Type-Dependent Replication of an Integrase-Defective Human Immunodeficiency Virus Type 1 in Human Primary Macrophages but Not T Lymphocytes. <i>Virology</i> , 1995, 208, 242-248.	1.1	59
88	Adhesion of Human Neuroblasts to HIV-1 tat. <i>Pediatric Research</i> , 1995, 38, 792-796.	1.1	6
89	Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. <i>Science</i> , 1994, 266, 801-805.	6.0	341
90	Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 8925-8928.	3.3	316

#	ARTICLE	IF	CITATIONS
91	Analysis of CD4 gene expression in human fetal brain and neuroblasts. Cellular and Molecular Neurobiology, 1992, 12, 131-141.	1.7	4
92	Neurite outgrowth and cell cycle kinetic changes induced by cis-diamminedichloroplatinum II and retinoic acid in a human neuroblastoma cell line. Cancer Letters, 1990, 52, 101-106.	3.2	16